In vitro validation of survivin as target tumor-associated antigen for immunotherapy in uterine cancer

Journal of Immunotherapy

Volumn 38, Issue 6, 2015, Pages 239-249

  Vanderstraeten, Anke ^a   Everaert, Tina ^a   Van Bree, Rieta ^a   Verbist, Godelieve ^b   Luyten, Cathérine ^a   Amant, Frederic ^b   Tuyaerts, Sandra ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

immunogenicity; spontaneous immune responses; survivin; tumor associated antigen; uterine cancer

Indexed keywords

CD137 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; MESSENGER RNA; SURVIVIN; TUMOR ANTIGEN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; T LYMPHOCYTE; TUMOR IMMUNITY; UTERUS CANCER; UTERUS SARCOMA; VALIDATION STUDY; CELL CULTURE; ENDOMETRIAL NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MOLECULARLY TARGETED THERAPY; PROCEDURES; SARCOMA; TREATMENT OUTCOME; UTERINE NEOPLASMS;

ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CELLS, CULTURED; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; SARCOMA; T-LYMPHOCYTES; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 84933512430     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000085     Document Type: Article

References (43)

1. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA. 2004;101: 15100-15105.
2. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.
3. Lambropoulou M, Papadopoulos N, Tripsianis G, et al. Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients. J Cancer Res Clin Oncol. 2010;136:427-435.
4. Brunner A, Riss P, Heinze G, et al. pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant. Br J Cancer. 2012;107:84-90.
5. Altieri DC. Targeting survivin in cancer. Cancer Lett. 2013; 332:225-228.
6. Rodel F, Sprenger T, Kaina B, et al. Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Curr Med Chem. 2012;19:3679-3688.
7. Knauer SK, Kramer OH, Knosel T, et al. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J. 2007;21:207-216.
8. Qi G, Tuncel H, Aoki E, et al. Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep. 2009;22:557-562.
9. Shinohara ET, Gonzalez A, Massion PP, et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer. 2005;103:1685-1692.
10. Kim J, McNiff JM. Nuclear expression of survivin portends a poor prognosis in Merkel cell carcinoma. Mod Pathol. 2008; 21:764-769.
11. Hui MK, Lai KK, Chan KW, et al. Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma. Med Oncol. 2012;29:3009-3016.
12. Saito T, Arifin MT, Hama S, et al. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol. 2007;82:193-198.
13. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323-5337.
14. Lladser A, Sanhueza C, Kiessling R, et al. Is survivin the potential Achilles' heel of cancer? Adv Cancer Res. 2011;111:1-37.
15. Andersen MH, Pedersen LO, Capeller B, et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61:5964-5968.
16. Heo CK, Bahk YY, Cho EW. Tumor-associated autoanti-bodies as diagnostic and prognostic biomarkers. BMB Rep. 2012;45:677-685.
17. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother. 2009;58:1535-1544.
18. Suppiah A, Greenman J. Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer. World J Gastroenterol. 2013;19:4651-4670.
19. Chen H, Werner S, Tao S, et al. Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer. Cancer Lett. 2014;346:178-187.
20. Healey GF, Lam S, Boyle P, et al. Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer. J Thorac Dis. 2013;5:618-625.
21. Karanikas V, Khalil S, Kerenidi T, et al. Anti-survivin antibody responses in lung cancer. Cancer Lett. 2009;282:159-166.
22. Megliorino R, Shi FD, Peng XX, et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev. 2005;29:241-248.
23. Rohayem J, Diestelkoetter P, Weigle B, et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 2000;60:1815-1817.
24. Grube M, Moritz S, Obermann EC, et al. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res. 2007;13:1053-1060.
25. Karanikas V, Soukou F, Kalala F, et al. Baseline levels of CD8 + T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals. Clin Immunol. 2008;129:230-240.
26. Li L, Wang K, Dai L, et al. Detection of autoantibodies to multiple tumor-associated antigens in the immunodiagnosis of ovarian cancer. Mol Med Rep. 2008;1:589-594.
27. Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol. 2009;115:112-120.
28. Soling A, Plugge EM, Schmitz M, et al. Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. Int J Oncol. 2007;30:123-128.
29. Yagihashi A, Asanuma K, Nakamura M, et al. Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem. 2001;47:1729-1731.
30. Wehler TC, Karg M, Distler E, et al. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. J Immunol Methods. 2008;339:23-37.
31. Wolfl M, Kuball J, Eyrich M, et al. Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A. 2008;73:1043-1049.
32. Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8 + T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110:201-210.
33. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006; 5:1087-1098.
34. Takai N, Miyazaki T, Nishida M, et al. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett. 2002;184:105-116.
35. Pallares J, Martinez-Guitarte JL, Dolcet X, et al. Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3. Int J Gynecol Pathol. 2005;24:247-253.
36. Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer. Clin Cancer Res. 2003;9: 4296-4303.
37. Turksma AW, Bontkes HJ, Ruizendaal JJ, et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med. 2013;11:152.
38. Bosscher JR, Gercel-Taylor C, Watkins CS, et al. Epitope recognition by anti-cathepsin D autoantibodies in endometrial cancer patients. Gynecol Oncol. 2001;81:138-143.
39. Uemura N, Kodama S, Nomi N, et al. Correlation between anti-survivin antibody and survivin mRNA expression in head and neck cancer patients. Acta Otolaryngol. 2010;130:959-965.
40. Chang JT, Wong FH, Liao CT, et al. Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem. 2004;50:1261-1264.
41. Eto M, Kodama S, Uemura N, et al. Antibody responses to survivin and their clinical significance in patients with head and neck cancer. Head Neck. 2007;29:1128-1135.
42. Leisegang M, Wilde S, Spranger S, et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Investig. 2010;120:3869-3877.
43. Hadrup SR, Gehl J, Sorensen RB, et al. Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission. Cancer Biol Ther. 2006;5:480-482.